How The Insulet (PODD) Narrative Is Shifting After Omnipod 5 Correction And Repriced Expectations

Insulet’s modeled fair value has been trimmed slightly from US$340.26 to US$326.35, indicating a more conservative price target in the updated analysis. This adjustment aligns with the mixed analyst ...

Why Insulet (PODD) Is Down 7.7% After FDA Class I Omnipod 5 Recall Expansion - And What's Next

In recent weeks, Insulet has expanded a voluntary Medical Device Correction and faced an FDA Class I recall of certain ...
Business Wire

Insulet Announces Full Commercial Launch of Omnipod 5 with Expanded Sensor Integrations in the United Kingdom and the Netherlands

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced ...
Healthline

Omnipod DASH vs. Omnipod 5: A Comparison

If you have type 1 diabetes, you know how difficult it can feel to manage your insulin levels and track your progress over time without turning it into something that resembles a full-time job. And ...